Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...
Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...
City of Hope, Duarte, California, United States
Emory Winship Cancer Institute, Atlanta, Georgia, United States
Northwestern, Chicago, Illinois, United States
Department of Medicine, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany
Childrens Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Suzhou Kowloon Hospital, Suzhou, Jiangsu, China
Childrens Hospital of Shanghai, Shanghai, Shanghai, China
Phoenix Children's Hospital, Phoenix, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
M D Anderson Cancer Center, Houston, Texas, United States
The first affiliated hospital of Soochow University, Suzhou, Jiangsu, China
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
Northside Hospital, Atlanta, Georgia, United States
North Adelaide- Womens and Childrens Hospital, Adelaide, Australia
Sydney Childrens Hospital, Sydney, Australia
The Childrens Hospital at Westmead, Westmead, Australia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.